Published in Cancer Res on November 01, 1978
A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg (1987) 2.54
Transcatheter intraarterial therapies: rationale and overview. Radiology (2011) 1.59
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol (2009) 1.50
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs (2000) 1.40
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol (2009) 1.39
Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intrahepatic chemotherapy. Ann Surg (1984) 1.23
The effects of intra-arterial vasoconstrictors on the distribution of a radiolabelled low molecular weight marker in an experimental model of liver tumour. Br J Cancer (1991) 1.14
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer (1988) 1.05
No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion. Br J Cancer (1992) 0.98
Hepatic arterial chemotherapy for metastatic colorectal carcinoma. Br J Cancer (1994) 0.98
Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol (2014) 0.96
Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo. Nucleic Acids Res (1984) 0.96
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol (2012) 0.95
Relationships between body composition parameters and fluorouracil pharmacokinetics. Br J Clin Pharmacol (2002) 0.95
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol (2010) 0.92
Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer (1994) 0.92
Colorectal liver metastases: is 'no treatment' still best? J R Soc Med (1989) 0.89
Cancer chemotherapy: new strategies for success. J Clin Invest (1986) 0.89
Conversion of encapsulated 5-fluoro-2'-deoxyuridine 5'-monophosphate to the antineoplastic drug 5-fluoro-2'-deoxyuridine in human erythrocytes. Proc Natl Acad Sci U S A (1988) 0.88
Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer. Mol Clin Oncol (2013) 0.81
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol (2012) 0.81
Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Cancer (1995) 0.80
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today (2012) 0.80
The combination of degradable starch microspheres and angiotensin II in the manipulation of drug delivery in an animal model of colorectal metastasis. Br J Cancer (1992) 0.79
Isolation-perfusion of the liver with 5-fluorouracil. Ann Surg (1985) 0.78
A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases. Br J Cancer (1994) 0.78
Transarterial approaches to primary and secondary hepatic malignancies. Nat Rev Clin Oncol (2015) 0.78
Liver Metastases. Curr Treat Options Gastroenterol (1999) 0.78
Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic cancer. Exp Ther Med (2011) 0.77
Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model. Clin Exp Metastasis (2000) 0.76
The re-birth of hepatic arterial infusion for colorectal liver metastases. J Gastrointest Oncol (2013) 0.76
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS One (2015) 0.75
Hepatic arterial infusion chemotherapy for post-operative liver metastases from pancreatic cancer in a patient with leukocytopenia: A case report. Exp Ther Med (2010) 0.75
Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. Int J Hepatol (2013) 0.75
[Intra-arterial treatment of liver metastases from colorectal carcinoma]. J Radiol (2011) 0.75
Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells. Br J Cancer (1999) 0.75
Primary hepatocellular carcinoma--recent advances and future prospects. West J Med (1985) 0.75
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer (1998) 0.75
Overall survival or other clinical benefits from adjuvant selective intraarterial chemotherapy in patients undergoing curative liver resection for metastatic colorectal tumor. Ann Surg (1999) 0.75
Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases. Int J Colorectal Dis (1996) 0.75
Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. Visc Med (2017) 0.75
J-tipped guidewire as a target for puncture of the subclavian artery in the placement of a reservoir port and catheter system. Eur Radiol (2003) 0.75
A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases. Int J Colorectal Dis (2015) 0.75
Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med (1994) 5.03
Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst (1998) 4.43
Hemodynamically significant primary anomalies of the coronary arteries. Angiographic aspects. Circulation (1978) 4.36
Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg (1993) 3.80
The DCC protein and prognosis in colorectal cancer. N Engl J Med (1996) 3.51
Efficient transfer of highly resolved small DNA fragments from polyacrylamide gels to DBM paper. Gene (1980) 3.30
Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys (1995) 3.20
Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med (1990) 3.09
Dose: a critical factor in cancer chemotherapy. Am J Med (1980) 2.82
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med (1975) 2.71
A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group B. JAMA (1993) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol (2001) 2.24
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med (1994) 2.20
Bacteremic hemophilus influenzae pneumonia in adults. A report of 24 cases and a review of the literature. Am J Med (1977) 2.04
Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med (1974) 2.02
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (1990) 1.93
Immediate reconstruction of the perineal wound with gracilis muscle flaps following abdominoperineal resection and intraoperative radiation therapy for recurrent carcinoma of the rectum. Ann Surg Oncol (1999) 1.88
Clinical trials with adriamycin. Cancer (1971) 1.86
Spilled gallstones after laparoscopic cholecystectomy. A relevant problem? A retrospective analysis of 10,174 laparoscopic cholecystectomies. Surg Endosc (1998) 1.77
Spiral computerized tomography in the evaluation of acute flank pain: a replacement for excretory urography. J Urol (1997) 1.77
Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg (1990) 1.76
A lesson from Canada: Ontario's health insurance. N Engl J Med (1978) 1.76
Carcinoembryonic antigen: clinical correlation with chemotherapy for metastatic gastrointestinal cancer. Cancer (1974) 1.74
Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst (1988) 1.73
Pathways and functional significance of the coronary collateral circulation. Circulation (1974) 1.72
Controlled multicenter trial of laparoscopic transabdominal preperitoneal hernioplasty vs Shouldice herniorrhaphy. Early results. Surg Endosc (1996) 1.71
Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am (2006) 1.70
The Polycomb-group gene, extra sex combs, encodes a nuclear member of the WD-40 repeat family. EMBO J (1995) 1.69
Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg (1980) 1.69
The relationship of clinical and academic productivity in a university hospital radiology department. AJR Am J Roentgenol (2000) 1.69
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys (1992) 1.66
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Complications of laparoscopic cholecystectomy in Switzerland. A prospective 3-year study of 10,174 patients. Swiss Association of Laparoscopic and Thoracoscopic Surgery. Surg Endosc (1998) 1.65
Use trends and geographic variation in neuroimaging: nationwide medicare data for 1993 and 1998. AJNR Am J Neuroradiol (2001) 1.61
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum (1983) 1.60
Frequency and clinical significance of failure to visualize the conus artery during coronary arteriography. Circulation (1981) 1.58
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells. Gastroenterology (1998) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Turf battles in radiology: how individual radiologists can respond to the challenge. Radiology (1998) 1.47
Experience with subcutaneous infusion ports in three hundred patients. Surg Gynecol Obstet (1988) 1.47
The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys (1990) 1.47
Combination cancer therapy: Presidential address. Cancer Res (1972) 1.47
Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen. Gastroenterology (1994) 1.45
The use of preoperative plasma CEA levels for the Stratification of patients after curative resection of colorectal cancers. Ann Surg (1980) 1.45
Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol (1983) 1.45
Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation (1982) 1.44
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res (1967) 1.44
Selection bias in clinical trials. J Clin Oncol (1985) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Angiographic demonstration of important anatomic variations of the posterior descending coronary artery. Am J Roentgenol Radium Ther Nucl Med (1972) 1.39
Low infusion rate digital subtraction angiography to predict regional perfusion in hepatic arterial chemotherapy. Cardiovasc Intervent Radiol (1990) 1.39
Preoperative Nyhus classification of inguinal hernias and type-related individual hernia repair. A case for diagnostic laparoscopy. Surg Laparosc Endosc (1997) 1.39
Practice patterns of radiologists and nonradiologists: nationwide Medicare data on the performance of chest and skeletal radiography and abdominal and pelvic sonography. AJR Am J Roentgenol (1998) 1.39
Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res (1983) 1.39
Complex regulation of early paired expression: initial activation by gap genes and pattern modulation by pair-rule genes. Development (1993) 1.39
[Early results of the initial 100 laparoscopic hernia operations under peridural anesthesia]. Schweiz Med Wochenschr (1995) 1.39
Incorporation of 5-bromo-2'-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7-day hepatic arterial infusion. Cancer Res (1995) 1.39
CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Ann Surg (1982) 1.38
Effect of adriamycin on the cell cycle traverse and kinetics of cultured human lymphoblasts. Cancer Res (1976) 1.38
Combined cyclophosphamide vincristine, and prednisone therapy of malignant lymphoma. Cancer (1971) 1.37
Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J Clin Oncol (1988) 1.37
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest (1984) 1.37
Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine. Clin Pharmacol Ther (1972) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
The step in cellular DNA synthesis blocked by Newcastle disease or mengovirus infection. Virology (1970) 1.34
The step in cellular DNA synthesis blocked by reovirus infection. Virology (1969) 1.34
Purification and physical-chemical characterization of hepatic stimulator substance. Hepatology (1987) 1.34
Dose schedule and antitumor studies of arabinosyl cytosine (NSC 63878). Cancer Res (1969) 1.33
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Cellular DNA and protein synthesis in reovirus-infected L cells. Virology (1969) 1.30
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. Cancer (1968) 1.28
The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol (2001) 1.27
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission. Ann Intern Med (1973) 1.27
The National Cancer Chemotherapy Program. Science (1982) 1.26
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Surgical considerations in the management of hepatic neoplasia. Semin Oncol (1983) 1.24
Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol (1993) 1.24
Cross-reacting tumor-associated antigen (s) among chemically induced rat colon carcinomas. Cancer Res (1974) 1.24
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood (1965) 1.23
Measurement of the electron charge asymmetry in inclusive W production in pp collisions at sqrt[s]=7 TeV. Phys Rev Lett (2012) 1.23
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res (1987) 1.23
Neuropsychological test performance in mildly hypoxemic patients with chronic obstructive pulmonary disease. J Consult Clin Psychol (1983) 1.23
double-time is identical to discs overgrown, which is required for cell survival, proliferation and growth arrest in Drosophila imaginal discs. Development (1999) 1.23
Progress and perspectives in the chemotherapy of acute leukemia. Adv Chemother (1965) 1.22
The effect of skin homograft rejection on recipient and donor mixed leukocyte cultures. J Exp Med (1965) 1.22
Physiologic effects of bronchopulmonary lavage in alveolar proteinosis. Am Rev Respir Dis (1978) 1.22
Cell proliferation in human melanoma. J Clin Invest (1970) 1.21
Mortality among workers exposed to polychlorinated biphenyls. Am J Epidemiol (1992) 1.21
A computer program for calculation and interpretation of pulmonary function studies. Chest (1975) 1.21